Investigator-Initiated Studies (IIS) play a critical role in advancing clinical knowledge, exploring novel endpoints, and generating real-world evidence in areas where traditional sponsored trials may not reach.
However, one persistent challenge remains:
How can investigator-led research teams collect robust, defensible clinical data without the infrastructure of a full CRO-sponsored clinical trial?
This is where 1Survey+ provides a unique solution.
The Challenge in Investigator-Initiated Studies
IIS projects often face structural constraints:
- Limited funding and operational resources
- Fragmented data capture systems
- Manual data verification processes
- Weak audit trails
- Limited 21 CFR Part 11-aligned infrastructure
- Uncertainty around regulatory expectations
While the scientific questions are often high-quality and innovative, the data collection tools used may not meet the level of rigor increasingly expected by regulators, ethics committees, or publication reviewers.
This creates risk — not only for regulatory defensibility, but also for scientific credibility.
Bridging the Infrastructure Gap
1Survey+ was designed to close this gap by offering:
- Clinical-grade survey methodology aligned to intended use
- Certified timestamping of data entry
- Immutable audit trails
- Traceable dataset verification
- Structured endpoint-focused data capture
- Compliance-by-design architecture
This allows IIS sponsors and investigators to collect high-quality data without the overhead of a traditional eCRF-heavy infrastructure.
Supporting Methodological Robustness
Investigator-led studies frequently focus on:
- Exploratory endpoints
- Biomarker compatibility
- Comparative performance observations
- Patient-reported outcomes
Through 1MED’s partnerships with KOL consultants in oncology, ophthalmology and cardiovascular medicine, IIS teams can also benefit from:
- Endpoint evaluation aligned with clinical relevance
- Independent adjudication frameworks
- Biomarker compatibility assessment
- Alignment with regulatory-grade evidence expectations
This ensures that the study is not only operationally sound, but scientifically defensible.
Regulatory Context: Why Infrastructure Matters
Even when an IIS does not fall under full regulatory clinical investigation requirements, data integrity expectations are increasing.
Under the EU Medical Device Regulation and global 21 CFR Part 11 expectations, traceability, timestamping, and auditability are no longer optional in high-quality evidence generation.
Publication reviewers, ethics committees, and potential future regulatory submissions may all scrutinize:
- Data authenticity
- Endpoint methodology
- Traceability of entries
- Evidence grading
A clinical-grade infrastructure protects the value of the research long-term.
From Data Collection to Evidence Ecosystem
Beyond individual studies, 1Survey+ enables:
- Scalable multi-center IIS data capture
- Structured aggregation of real-world evidence
- Integration into PMCF strategies
- Future Digital Product Passport alignment
- AI-supported signal identification
This transforms IIS from isolated academic exercises into strategically valuable evidence generators.
A Flexible, Scalable Model
For IIS environments, flexibility is critical.
1Survey+ allows:
- Rapid study setup
- Custom endpoint structuring
- Device-agnostic deployment
- Secure web-based access
- Scalable expansion from pilot to multi-site study
This supports investigator autonomy while ensuring regulatory robustness.
Elevating Investigator-Led Research
The future of medical innovation increasingly depends on real-world insight generated by clinical leaders.
By combining:
- Certified data integrity
- Intended-use–driven methodology
- Scientific endpoint advisory support
1Survey+ enables investigator-initiated studies to generate data that is:
- Scientifically credible
- Audit-ready
- Publication-grade
- Regulatory-grade
Because in modern clinical research, it is not only the question that matters — it is the defensibility of the answer.
Book a demo with us to disocver more about 1Survey+ at demo@1med.net
